ReviewCurrent neurology and neuroscience reports2010
Ependymomas in adults.
Review in Current neurology and neuroscience reports, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03173950 (Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients With Recurrent Select Rare CNS Cancers), which is not on this map. Cited by 70 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients With Recurrent Select Rare CNS Cancers
Who cites it
70 citing papers in PubMed, 2 syntheses or guidelines pooled it, 143 citations in OpenAlex.
- Spinal cord ependymomas and the appearance of other de novo tumors: a systematic review.Journal of medical case reports · 2014Pooled it
- Histologic grade and extent of resection are associated with survival in pediatric spinal cord ependymomas.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2013Pooled it
- Effect of radiation on patients with grade 2 intramedullary spine ependymoma.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2026Article
- Survival Patterns and Mortality Causes in Patients with Invasive Ependymoma: A Retrospective Cohort Analysis from 2000 to 2019.Medical sciences (Basel, Switzerland) · 2025Article
- Liquid Biopsy for Spinal Tumors: On the Frontiers of Clinical Application.Global spine journal · 2025Article
- Intracranial ependymoma: A retrospective analysis of clinical features, treatment modalities, and long-term outcome.Aging medicine (Milton (N.S.W)) · 2024Article
- The Role of Radiotherapy, Chemotherapy, and Targeted Therapies in Adult Intramedullary Spinal Cord Tumors.Cancers · 2024Review
- Modeling of brain tumors usingHeliyon · 2024Review
- Technical aspects of fourth ventricle ependymomas in adults: how I do it.Acta neurochirurgica · 2024Review
- Clinical presentation and extent of resection impacts progression-free survival in spinal ependymomas.Journal of neuro-oncology · 2024Article
- Neurologic outcomes for adult spinal cord ependymomas stratified by tumor location: a retrospective cohort study and 2-year outlook.Neurosurgical review · 2023Article
- Adult intracranial ependymoma-relevance of DNA methylation profiling for diagnosis, prognosis, and treatment.Neuro-oncology · 2023Article
- A cystic anaplastic ependymoma mimicking a pilocytic astrocytoma.Radiology case reports · 2023Article
- Spinal ependymoma in adults: from molecular advances to new treatment perspectives.Frontiers in oncology · 2023Review
- Ependymoma: Evaluation and Management Updates.Current oncology reports · 2022Review
- Holistic Approach to the Diagnosis and Treatment of Patients with Tumor Metastases to the Spine.Cancers · 2022Review
- Article
- Glioma-Targeted Therapeutics: Computer-Aided Drug Design Prospective.The protein journal · 2021Review
- Review
- Complete Versus Incomplete Surgical Resection in Intramedullary Ependymomas: A Systematic Review and Meta-analysis.Global spine journal · 2021Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ependymomas are rare primary central nervous system tumors in adults. They occur most commonly in the spinal cord, where histopathologic evaluation is critical to differentiate the grade I myxopapillary ependymoma from the grade II ependymoma or grade III anaplastic ependymoma. Brain ependymomas are either grade II or III. Treatment for all grades and types includes maximum surgical resection. For myxopapillary ependymoma, complete removal while maintaining capsule integrity may be curative. Some grade II ependymomas may be observed carefully after imaging confirms complete resection, but grade III tumors require adjuvant radiation treatment. Radiation commonly is given to the region of tumor, except in cases in which there is imaging or cerebrospinal fluid evidence of tumor dissemination. Chemotherapy has not been studied extensively, although most reports suggest only modest benefit. Ongoing laboratory studies have uncovered important signal transduction pathways that may be better therapeutic targets, leading to the development of clinical trials using targeted agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.